Cancer and Metastasis Reviews, published by Springer, is a leading journal in the field of oncology and cancer research. With an impressive impact factor placing it in the Q1 category for both Cancer Research and Oncology as of 2023, this journal is ranked 29th out of 404 in Medicine, Oncology, and 22nd out of 230 in Biochemistry, Genetics, and Molecular Biology, reflecting its significant influence and prestige in the academic community. Established in 1982, the journal covers a wide spectrum of topics related to the mechanisms of cancer progression and metastasis, making it an essential resource for researchers, healthcare professionals, and students dedicated to understanding and tackling cancer. Although the journal does not provide open access options, the impactful research it publishes contributes to advances in therapeutic strategies and enhances the collective knowledge surrounding cancer pathophysiology. With research converging from 1982 to 2024, Cancer and Metastasis Reviews continues to be a vital platform for disseminating high-quality scientific information in the ever-evolving landscape of cancer research.

ONCOLOGY RESEARCH, published by TECH SCIENCE PRESS, is a vital academic journal dedicated to the rapidly evolving field of oncology. With its ISSN 0965-0407 and E-ISSN 1555-3906, the journal serves as a key resource for researchers, clinicians, and academicians committed to advancing cancer research and treatment strategies. Operating without an Open Access model, ONCOLOGY RESEARCH provides high-quality, peer-reviewed articles that cover diverse topics within cancer research, medicine, and oncology, with its 2023 Scopus ranking placing it in the Q3 quartile. The journal's commitment to facilitating rigorous scientific discourse is evident in its historical breadth, with a publishing history dating back to 1992. ONCOLOGY RESEARCH is not only significant for the academic community but also plays a critical role in fostering new insights and approaches in the fight against cancer, making it a must-read for those involved in this critical area of study.

MOLECULAR & CELLULAR PROTEOMICS, published by Elsevier, stands as a premier journal in the fields of Biochemistry, Analytical Chemistry, and Molecular Biology, with a distinguished Q1 ranking reflecting its high impact and contribution to the scientific community. Established in 2002, this journal has consistently provided a platform for the latest research in protein science, merging molecular biology with advanced analytical techniques. With impressive Scopus rankings—41st in Biochemistry and 16th in Analytical Chemistry—it caters to an audience of researchers, professionals, and students eager to explore cutting-edge developments in proteomics. Although currently not designated as open access, the journal aims to foster knowledge dissemination through accessible research content. As it continues to evolve until 2024, MOLECULAR & CELLULAR PROTEOMICS is essential for anyone passionately engaged in the ever-expanding field of proteomics.

Cancer Genetics is an esteemed peer-reviewed journal dedicated to advancing the field of cancer research through the lens of genetics. Published by Elsevier Science Inc and available in both print (ISSN: 2210-7762) and online (E-ISSN: 2210-7770), this journal aims to provide a platform for the dissemination of high-quality studies that unravel the genetic underpinnings of cancer. Since its inception in 2011, Cancer Genetics has become a significant resource for researchers, professionals, and students with a shared interest in understanding the intricate relationship between genetics and oncogenesis. With an impact factor that reflects its influence, the journal has maintained a Q3 ranking in Cancer Research, Genetics, and Molecular Biology as of 2023, indicating its growing importance in these fields. Additionally, the journal offers open access options to ensure that crucial findings are easily accessible to the global research community. By bridging the gap between genetics and cancer studies, Cancer Genetics plays a pivotal role in fostering innovation and collaboration among scientists and clinicians striving to improve cancer diagnosis and treatment.

PATHOLOGY RESEARCH AND PRACTICE is a premier journal in the field of pathology and forensic medicine, published by Elsevier GmbH in Germany. With a rich publication history since 1978 and an impressive convergence period extending to 2024, this journal serves as a vital resource for researchers and professionals dedicated to advancing the understanding of pathological processes. It holds notable rankings, including Q3 in Cell Biology and Q2 in Pathology and Forensic Medicine for 2023, reflecting its significance in the academic community. The journal aims to publish innovative research findings, reviews, and case studies, facilitating a deeper understanding of disease mechanisms and improving diagnostic practices. Authors and readers alike benefit from its reputable platform, noted for its challenging and rigorous peer-review process. By fostering a collaborative environment and providing open access options, PATHOLOGY RESEARCH AND PRACTICE continues to contribute meaningfully to the discourse within its respective fields, thereby appealing to a diverse audience of researchers, professionals, and students.

Translational Cancer Research, published by AME Publishing Company in Hong Kong, is a pivotal journal aimed at fostering the advancement of oncology-related knowledge through the dissemination of high-quality research findings. With its ISSN 2218-676X and E-ISSN 2219-6803, this journal serves as a vital resource for researchers, professionals, and students in the fields of Cancer Research, Oncology, and Radiology, Nuclear Medicine, and Imaging. Established in 2012, the journal covers the latest breakthroughs and cross-disciplinary approaches that drive innovation in cancer treatment and diagnostics. Although currently classified in the Q4 Quartile for Cancer Research and Q3 for both Oncology and Radiology, Translational Cancer Research continuously works toward improving its academic influence and impact, evidenced by its ongoing research contributions. The journal emphasizes open access, making crucial research available to a global audience. We invite scholars and industry professionals to engage with the latest findings and discussions within these critical areas of medical science.

EXPERIMENTAL CELL RESEARCH is a highly respected journal published by Elsevier Inc, specializing in the dynamic and ever-evolving field of Cell Biology. With an impact factor positioned in the Q2 quartile for 2023, it ranks at the 124th position out of 285 in the Scopus Ranks, indicating a solid reputation among peers in the domains of biochemistry, genetics, and molecular biology. Since its inception in 1950, the journal has contributed significantly to the dissemination of groundbreaking research, providing a platform for studies that explore the nuances of cellular mechanisms, processes, and experimental methodologies. Although the journal currently does not offer open access, its commitment to high-quality, peer-reviewed research continues to attract submissions from leading scientists and scholars across the globe. Researchers, professionals, and students alike will find this journal an invaluable resource for keeping abreast of current developments and innovative breakthroughs in cellular science.

BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE, published by Elsevier, is a pivotal journal in the fields of Molecular Biology and Molecular Medicine, recognized for its high impact factor and robust ranking within Scopus categories, holding prestigious quartiles in Q1 for both disciplines as of 2023. With ISSN 0925-4439 and E-ISSN 1879-260X, this journal fosters cutting-edge research from 1990 to 2025, addressing the critical molecular mechanisms underlying human diseases. Its wide-ranging scope includes original research articles, reviews, and advanced theoretical insights, serving as an essential resource for researchers, clinicians, and students alike. The journal is based in the Netherlands, at RADARWEG 29, 1043 NX AMSTERDAM, and while it does not currently offer an open-access option, it continues to maintain a strong presence in the scientific community, enhancing our understanding of molecular processes in health and disease.

ONCOGENE is a premier peer-reviewed journal published by SpringerNature, serving as a crucial platform for innovative research within the fields of Cancer Research, Genetics, and Molecular Biology. With an impressive Impact Factor and a distinguished Q1 ranking across major categories, ONCOGENE publishes cutting-edge studies aimed at unraveling the complexities of cancer biology and genetic mechanisms. The journal has been a vital resource for the academic community since its inception in 1987, and it continues to foster rigorous scientific discussions and collaborations. Researchers, professionals, and students can access a wealth of critical insights and advances in cancer genomics and therapeutic approaches, cementing ONCOGENE’s role as a leading voice in the landscape of biomedical research. For comprehensive academic research, ONCOGENE remains an indispensable source of knowledge with contributions that significantly impact the evolution of cancer research and treatment strategies.

Molecular & Cellular Oncology, published by Taylor & Francis Inc, is a vital academic journal dedicated to the exploration of cancer biology through the lens of molecular and cellular mechanisms. Since its inception in 2014, the journal has played a crucial role in disseminating innovative research findings that address the fundamental aspects of cancer research and molecular medicine. With its current ranking in Scopus placing it in the Q3 quartile for both Cancer Research and Molecular Medicine, the journal provides a platform for groundbreaking studies that push the boundaries of our understanding of oncogenesis and therapeutic interventions. Although the journal operates under a subscription model, its dedication to high-quality peer-reviewed research makes it an essential resource for researchers, professionals, and students aiming to contribute to or stay updated in the rapidly evolving field of oncology. As we approach the culmination of its converged years in 2024, Molecular & Cellular Oncology aims to continue fostering collaborations and insights that advance cancer research on a global scale.